#HVO hVIVO PLC – Shionogi reports positive RSV trial results February 5, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, notes the announcement by Shionogi & Co., Ltd. (“Shionogi”), reporting positive results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) conducted by hVIVO. The trial demonstrated a significant reduction in viral load for Shionogi’s investigational oral RSV antiviral candidate, S-337395.   S-337395, which has received Fast Track designation from the U.S.…

Continue reading